Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Financings of the Fortnight Wants To Spin You Right 'Round, And Out

This article was originally published in The Pink Sheet Daily

Executive Summary

Recently public Akebia is just one of the many biotechs making a case for spin-outs driven by economic needs. Also, Sangamo, Ataxion, Galmed and SAGE tap the financing pool.

You may also be interested in...



Atlas-Backed Firm Will Seek Pan-Ataxia Therapy With Biogen’s Assistance

Biogen participates with Atlas Venture in a $17 million Series A financing for Ataxion, which will seek to advance preclinical ion channel modulators for hereditary ataxias.

With Shire Behind Him, Jonas Starts New Chapter At SAGE

The upbeat ex-Shire exec has moved on from his tumultuous break-up with the specialty pharma and is on day three in his new role as CEO of CNS start-up SAGE Therapeutics. He will focus on bringing CNS products forward for orphan indications.

Market Snapshot: Diabetic Macular Edema, Another Blockbuster Opportunity For Retinal Drugs?

Having relatively rapidly built a multi-billion dollar market in wet age-related macular degeneration, biotech and pharma companies may be about to repeat the exercise with diabetic macular edema, a complication of diabetes that’s growing in importance as the population ages and the disease spreads.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS076987

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel